GlassScriptPhysician profile
Vinay Gutti
NPI 1942400262
$41,997.77
in general payments reported to CMS, 2019-2025
21 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,503 · 2021: $4,859 · 2022: $2,631 · 2023: $2,392 · 2024: $5,917 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $6,176 · Travel and Lodging: $795 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,761.16 |
| Food and Beverage | $6,175.93 |
| Travel and Lodging | $794.66 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $21,601.23 | 2019-2025 | Tecnis Iol, Catalys System, Veritas Vision System |
| Glaukos Corporation | $13,193.75 | 2019-2025 | Travoprost Intraocular Implant - Idose, Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Novartis Pharmaceuticals Corporation | $1,651.31 | 2019-2023 | |
| Abbvie INC. | $1,581.45 | 2022-2025 | |
| New World Medical,INC. | $921.74 | 2024-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Ocular Therapeutix, INC. | $733.47 | 2023-2025 | Dextenza |
| Alcon Vision LLC | $494.83 | 2021-2025 | Clareon Panoptix Pro, Clareon, Hydrus Microstent |
| Sight Sciences, INC. | $459.57 | 2021-2024 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $363.94 | 2023-2025 | Xiidra, Miebo |
| Nova Eye, INC. | $303.99 | 2024 | |
| Shire North American Group INC | $147.98 | 2019 | |
| Allergan, INC. | $141.33 | 2020-2022 | |
| Biotissue Holdings INC. | $106.80 | 2021-2025 | |
| Rxsight INC | $78.18 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Aerie Pharmaceuticals, INC. | $77.88 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $48.94 | 2019-2020 | |
| Dompe US, INC. | $22.97 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $18.62 | 2025 | |
| Eyevance Pharmaceuticals LLC | $17.67 | 2021 | |
| Rayner Intraocular Lenses Limited | $17.19 | 2024 | Rayone Emv, Rayone Spheric, Omidria |
| Eyepoint US, INC. | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Gutti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.